Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.

Saved in:

Bibliographic Details
Title:	Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Authors:	Han K; Clinical Pharmacology, Genentech Inc, South San Francisco, CA, USA., Jin JY; Clinical Pharmacology, Genentech Inc, South San Francisco, CA, USA., Marchand M; Pharsight Consulting Services, Pharsight, a Certara™ Company, Marseille, France., Eppler S; Clinical Pharmacology, Genentech Inc, South San Francisco, CA, USA., Choong N; Product Development Oncology, Genentech Inc, South San Francisco, CA, USA., Hack SP; Product Development Oncology, Genentech Inc, South San Francisco, CA, USA., Tikoo N; Statistical Programming Analysis, Genentech Inc, South San Francisco, CA, USA., Bruno R; Pharsight Consulting Services, Pharsight, a Certara™ Company, Marseille, France., Dresser M; Clinical Pharmacology, Genentech Inc, South San Francisco, CA, USA., Musib L; Clinical Pharmacology, Genentech Inc, South San Francisco, CA, USA., Budha NR; Clinical Pharmacology, Genentech Inc, South San Francisco, CA, USA. budha.nageshwar@gene.com.
Source:	Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2015 Nov; Vol. 76 (5), pp. 917-24. Date of Electronic Publication: 2015 Sep 13.
Publication Type:	Comparative Study; Journal Article
Journal Info:	Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1432-0843
DOI:	10.1007/s00280-015-2862-0